Detection of carbonic anhydrase-9 gene expression in peripheral blood cells predicts risk of disease recurrence in patients with renal cortical tumors

Scott M. Gilbert, Jared M Whitson, Mahesh Mansukhani, Ralph Buttyan, Mitchell C. Benson, Carl A. Olsson, Ihor S. Sawczuk, James M. McKiernan

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Objectives: To present extended follow-up on a cohort of patients with renal cortical tumors treated with partial or radical nephrectomy and preoperatively assess for carbonic anhydrase 9 tumor marker expression in the peripheral blood. Methods: All patients were originally enrolled in an institutional review board-approved study assessing the role of a reverse-transcriptase polymerase chain reaction peripheral blood assay designed to detect the tumor-specific gene carbonic anhydrase-9 (CA9). A total of 41 patients with renal cortical tumors confined to the kidney were enrolled at a single institution and assessed preoperatively with peripheral blood test for CA9 expression before undergoing partial or radical nephrectomy. A Kaplan-Meier estimated survival analysis and log-rank test were performed to determine whether detection of peripheral blood cells expressing the CA9 gene influences disease-free and disease-specific survival. Results: The median follow-up was 4.3 years. The median age was 71 years. Of the 41 patients, 26 were men and 15 were women. The estimated 5-year disease-free survival for patients with detectible expression of the CA9 gene in the peripheral blood was 39.5% compared with 88.1% for patients without detection of the CA9 gene (P = 0.048). On bivariate analysis, disease-free survival correlated with histologic type, tumor diameter, and tumor grade. Conclusions: The expression of the tumor-specific marker CA9 in the peripheral blood is associated with decreased disease-free survival in patients with renal cortical tumors. This is the first study reporting on the prognostic value of this peripheral blood-based tumor marker for kidney tumors.

Original languageEnglish (US)
Pages (from-to)942-945
Number of pages4
JournalUrology
Volume67
Issue number5
DOIs
StatePublished - May 2006
Externally publishedYes

Fingerprint

Blood Cells
Kidney
Gene Expression
Recurrence
Disease-Free Survival
Tumor Biomarkers
Neoplasms
Nephrectomy
Genes
Research Ethics Committees
Hematologic Tests
Survival Analysis
Carbonic Anhydrase IX
Reverse Transcriptase Polymerase Chain Reaction

ASJC Scopus subject areas

  • Urology

Cite this

Gilbert, S. M., Whitson, J. M., Mansukhani, M., Buttyan, R., Benson, M. C., Olsson, C. A., ... McKiernan, J. M. (2006). Detection of carbonic anhydrase-9 gene expression in peripheral blood cells predicts risk of disease recurrence in patients with renal cortical tumors. Urology, 67(5), 942-945. https://doi.org/10.1016/j.urology.2005.11.034

Detection of carbonic anhydrase-9 gene expression in peripheral blood cells predicts risk of disease recurrence in patients with renal cortical tumors. / Gilbert, Scott M.; Whitson, Jared M; Mansukhani, Mahesh; Buttyan, Ralph; Benson, Mitchell C.; Olsson, Carl A.; Sawczuk, Ihor S.; McKiernan, James M.

In: Urology, Vol. 67, No. 5, 05.2006, p. 942-945.

Research output: Contribution to journalArticle

Gilbert, SM, Whitson, JM, Mansukhani, M, Buttyan, R, Benson, MC, Olsson, CA, Sawczuk, IS & McKiernan, JM 2006, 'Detection of carbonic anhydrase-9 gene expression in peripheral blood cells predicts risk of disease recurrence in patients with renal cortical tumors', Urology, vol. 67, no. 5, pp. 942-945. https://doi.org/10.1016/j.urology.2005.11.034
Gilbert, Scott M. ; Whitson, Jared M ; Mansukhani, Mahesh ; Buttyan, Ralph ; Benson, Mitchell C. ; Olsson, Carl A. ; Sawczuk, Ihor S. ; McKiernan, James M. / Detection of carbonic anhydrase-9 gene expression in peripheral blood cells predicts risk of disease recurrence in patients with renal cortical tumors. In: Urology. 2006 ; Vol. 67, No. 5. pp. 942-945.
@article{a30fcbdf7649481d98599efe5a92c838,
title = "Detection of carbonic anhydrase-9 gene expression in peripheral blood cells predicts risk of disease recurrence in patients with renal cortical tumors",
abstract = "Objectives: To present extended follow-up on a cohort of patients with renal cortical tumors treated with partial or radical nephrectomy and preoperatively assess for carbonic anhydrase 9 tumor marker expression in the peripheral blood. Methods: All patients were originally enrolled in an institutional review board-approved study assessing the role of a reverse-transcriptase polymerase chain reaction peripheral blood assay designed to detect the tumor-specific gene carbonic anhydrase-9 (CA9). A total of 41 patients with renal cortical tumors confined to the kidney were enrolled at a single institution and assessed preoperatively with peripheral blood test for CA9 expression before undergoing partial or radical nephrectomy. A Kaplan-Meier estimated survival analysis and log-rank test were performed to determine whether detection of peripheral blood cells expressing the CA9 gene influences disease-free and disease-specific survival. Results: The median follow-up was 4.3 years. The median age was 71 years. Of the 41 patients, 26 were men and 15 were women. The estimated 5-year disease-free survival for patients with detectible expression of the CA9 gene in the peripheral blood was 39.5{\%} compared with 88.1{\%} for patients without detection of the CA9 gene (P = 0.048). On bivariate analysis, disease-free survival correlated with histologic type, tumor diameter, and tumor grade. Conclusions: The expression of the tumor-specific marker CA9 in the peripheral blood is associated with decreased disease-free survival in patients with renal cortical tumors. This is the first study reporting on the prognostic value of this peripheral blood-based tumor marker for kidney tumors.",
author = "Gilbert, {Scott M.} and Whitson, {Jared M} and Mahesh Mansukhani and Ralph Buttyan and Benson, {Mitchell C.} and Olsson, {Carl A.} and Sawczuk, {Ihor S.} and McKiernan, {James M.}",
year = "2006",
month = "5",
doi = "10.1016/j.urology.2005.11.034",
language = "English (US)",
volume = "67",
pages = "942--945",
journal = "Urology",
issn = "1527-9995",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Detection of carbonic anhydrase-9 gene expression in peripheral blood cells predicts risk of disease recurrence in patients with renal cortical tumors

AU - Gilbert, Scott M.

AU - Whitson, Jared M

AU - Mansukhani, Mahesh

AU - Buttyan, Ralph

AU - Benson, Mitchell C.

AU - Olsson, Carl A.

AU - Sawczuk, Ihor S.

AU - McKiernan, James M.

PY - 2006/5

Y1 - 2006/5

N2 - Objectives: To present extended follow-up on a cohort of patients with renal cortical tumors treated with partial or radical nephrectomy and preoperatively assess for carbonic anhydrase 9 tumor marker expression in the peripheral blood. Methods: All patients were originally enrolled in an institutional review board-approved study assessing the role of a reverse-transcriptase polymerase chain reaction peripheral blood assay designed to detect the tumor-specific gene carbonic anhydrase-9 (CA9). A total of 41 patients with renal cortical tumors confined to the kidney were enrolled at a single institution and assessed preoperatively with peripheral blood test for CA9 expression before undergoing partial or radical nephrectomy. A Kaplan-Meier estimated survival analysis and log-rank test were performed to determine whether detection of peripheral blood cells expressing the CA9 gene influences disease-free and disease-specific survival. Results: The median follow-up was 4.3 years. The median age was 71 years. Of the 41 patients, 26 were men and 15 were women. The estimated 5-year disease-free survival for patients with detectible expression of the CA9 gene in the peripheral blood was 39.5% compared with 88.1% for patients without detection of the CA9 gene (P = 0.048). On bivariate analysis, disease-free survival correlated with histologic type, tumor diameter, and tumor grade. Conclusions: The expression of the tumor-specific marker CA9 in the peripheral blood is associated with decreased disease-free survival in patients with renal cortical tumors. This is the first study reporting on the prognostic value of this peripheral blood-based tumor marker for kidney tumors.

AB - Objectives: To present extended follow-up on a cohort of patients with renal cortical tumors treated with partial or radical nephrectomy and preoperatively assess for carbonic anhydrase 9 tumor marker expression in the peripheral blood. Methods: All patients were originally enrolled in an institutional review board-approved study assessing the role of a reverse-transcriptase polymerase chain reaction peripheral blood assay designed to detect the tumor-specific gene carbonic anhydrase-9 (CA9). A total of 41 patients with renal cortical tumors confined to the kidney were enrolled at a single institution and assessed preoperatively with peripheral blood test for CA9 expression before undergoing partial or radical nephrectomy. A Kaplan-Meier estimated survival analysis and log-rank test were performed to determine whether detection of peripheral blood cells expressing the CA9 gene influences disease-free and disease-specific survival. Results: The median follow-up was 4.3 years. The median age was 71 years. Of the 41 patients, 26 were men and 15 were women. The estimated 5-year disease-free survival for patients with detectible expression of the CA9 gene in the peripheral blood was 39.5% compared with 88.1% for patients without detection of the CA9 gene (P = 0.048). On bivariate analysis, disease-free survival correlated with histologic type, tumor diameter, and tumor grade. Conclusions: The expression of the tumor-specific marker CA9 in the peripheral blood is associated with decreased disease-free survival in patients with renal cortical tumors. This is the first study reporting on the prognostic value of this peripheral blood-based tumor marker for kidney tumors.

UR - http://www.scopus.com/inward/record.url?scp=33646845097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646845097&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2005.11.034

DO - 10.1016/j.urology.2005.11.034

M3 - Article

C2 - 16698354

AN - SCOPUS:33646845097

VL - 67

SP - 942

EP - 945

JO - Urology

JF - Urology

SN - 1527-9995

IS - 5

ER -